The role of uroselective α1AAR antagonists in the treatment of BPH

The role of uroselective α1AAR antagonists in the treatment of BPH

A badge with ribbon in color black Point(s): 1 | An analog clock in color black 20 minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 19 Feb 2022 



The goal of this learning activity is to provide doctors with a comprehensive review of the impact of subtype-selective α1-adrenergic receptor ( α1AR) antagonists in the treatment of benign prostatic hyperplasia (BPH). 

Upon completing this module, participants will have a better understanding of the following aspects:
• Epidemiology of BPH
• Pathophysiology of BPH
• Evaluation and management of lower urinary tract symptoms (LUTS)
• Safety and efficacy of selective α1AAR antagonists 

CPD Reviewer:

Professor Dr Ong Teng Aik

Head of the Division of Urology

University Malaya Medical Centre

Please read thoroughly & understand the module before attempting the assessment questions.

Terms & Conditions: 
■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point. 
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points. 

The modules/articles are best viewed with:

Google Chrome, Firefox, Internet Explorer, Safari or any other W3C standards compliant browser may be required to view the modules.

Sponsored by: